SBUX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Starbucks Corp (SBUX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the company has shown some positive developments, including revenue growth and innovative initiatives like AI integration, the significant decline in net income, EPS, and gross margin, coupled with cautious trading sentiment and recent congress sale transactions, suggest a wait-and-see approach. The stock's pre-market decline and mixed analyst ratings further support holding off on immediate investment.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 65.927, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 98.46, with resistance at 100.747 and support at 96.174. However, the pre-market price is down 0.55%, indicating short-term weakness.
Starbucks integrated ChatGPT for customer experience enhancement, which could attract more digital users.
The company opened 128 net new stores in Q1 2026, showing global expansion.
Starbucks revamped its loyalty program, which accounted for 60% of revenue in fiscal
Revenue increased by 6% YoY in Q1 2026, reflecting solid sales trends.
Net income dropped by 62.44% YoY in Q1 2026, indicating profitability challenges.
EPS and gross margin also declined significantly, down 62.32% and 15.48% YoY, respectively.
Congress trading data shows a recent sale transaction, indicating cautious sentiment.
Analysts have mixed ratings, with some downgrades citing valuation concerns and execution risks.
In Q1 2026, Starbucks reported a 6% YoY revenue increase to $9.92 billion. However, net income dropped by 62.44% to $293.3 million, and EPS fell by 62.32% to $0.26. Gross margin also declined by 15.48% to 17.03%. These figures highlight growth in revenue but significant challenges in profitability.
Analyst ratings are mixed. JPMorgan, Stifel, and Tigress Financial maintain positive ratings with price targets of $100, $115, and $122, respectively, citing solid domestic sales and operational improvements. However, firms like Citi, RBC Capital, and Wolfe Research express concerns over valuation, execution risks, and competitive pressures, with some downgrades to Neutral or Hold.
